Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
View Top Employees from Adrenomed AGWebsite | http://adrenomed.com |
Revenue | $3 million |
Employees | 28 (27 on RocketReach) |
Founded | 2009 |
Address | Neuendorfstr. 15a, Hennigsdorf, Brandenburg 16761, DE |
Phone | +49 3302 207780 |
Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Business Services General, Medical, Business Services, Health Care, Pharmaceutical |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular Adrenomed AG employee's phone or email?
The Adrenomed AG annual revenue was $3 million in 2024.
Jens Schneider-Mergener is the CEO of Adrenomed AG.
27 people are employed at Adrenomed AG.
Adrenomed AG is based in Hennigsdorf, Brandenburg.
The NAICS codes for Adrenomed AG are [54171, 541, 541713, 54, 5417].
The SIC codes for Adrenomed AG are [87, 873].